Volume 2, Number 4 (July/August 2004)

Bench to Bedside

305

  

Mechanism of Action of Cannabinoids: How It May Lead to Treatment of Cachexia, Emesis, and Pain
Billy R. Martin, PhD, and Jenny L. Wiley, PhD

Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia

With peer viewpoints by John S. Macdonald, MD, St. Vincent’s Comprehensive Cancer Center, New York, New York, and Mark A. Ware, MBBS, MRCP(UK), MSc, McGill University, Montreal, Quebec, Canada

abstract full text 181 kb

323

  

Pathophysiology and Palliation of Inoperable Bowel Obstruction in Patients With Ovarian Cancer
Aminah Jatoi, MD, Karl C. Podratz, MD, PhD, Paula Gill, MD, and Lynn C. Hartmann, MD

Divisions of Medical Oncology and Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota

With peer viewpoints by William J. Hoskins, MD, Curtis and Elizabeth Anderson Cancer Institute, Memorial Health University Medical Center, Savannah, Georgia, and J. Cameron Muir, MD, Capital Hospice, Fairfax, Virginia

abstract full text 230 kb

339

  

Minimally Invasive Treatments for Spinal Metastases: Vertebroplasty, Kyphoplasty, and Radiofrequency Ablation
Ryan J. Halpin, BS, Bernard R. Bendok, MD, and John C. Liu, MD

Northwestern University Feinberg School of Medicine, Chicago, Illinois

With peer viewpoints by Choll W. Kim, MD, PhD, and Steve Gar. n, MD, University of California, San Diego, California, and Nora A. Janjan, MD, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

abstract full text 278 kb

How We Do It

357

  

How to Use Octreotide for Malignant Bowel Obstruction
Carla Ripamonti, MD, and Sebastiano Mercadante, MD

Palliative Care Operative Unit, National Cancer Institute of Milan, Milan, Italy, and La Maddalena Cancer Center, Palermo, Italy

full text 168 kb

How We Say It

301

  

Words and Our Way With Them
By Michael Rowe, PhD

Department of Psychiatry, Yale University, New Haven, Connecticut

full text 46 kb

Clinical Trials

302

  

Clinical Trials in Supportive Care
Prevention and Treatment of Bone Metastases

full text 46 kb

Observations

319

  

Earlier Initiation of Treatment Recommended in Using Erythropoietic Agents for Chemotherapy-Induced Anemia

full text 34 kb

319

  

NCCN Makes Changes to Its Guidelines for Treating Fever and Neutropenia

full text 37 kb

366

  

NCCN Antiemesis Guidelines Emphasize 'Delayed' Emesis, New 5-HT3 Inhibitors, and NK-1 Blockers

full text 42 kb

Announcements

364

  

New Nursing Task Force to Focus on Chemotherapy-Related Anemia

full text 30 kb

Reader Services

298

  

Guide for Authors

© 2004 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.